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Research
Bisphenol A (BPA) is a chemical produced in 
very high volume, with > 2 million metric tons 
produced worldwide in 2003 (Vandenberg 
et al. 2009) and used extensively in the 
manufacture of epoxy resins, polycarbonate 
plastics, and food and beverage containers 
(Vandenberg et al. 2009). Consequently, it 
is one of the most common environmental 
chemical exposures in humans (Calafat et al. 
2005). Data from the nationally representative 
National Health and Nutrition Examination 
Survey (NHANES) suggest that detectable 
levels of BPA are present in the urine of a 
majority of U.S. adults (Calafat et al. 
2005, 2008).
BPA is considered to be an endocrine-
disrupting chemical, and it has been shown 
to have estrogenic and thyroid hormone–
disrupting effects in experimental studies 
(Moriyama et al. 2002; Vandenberg et al. 
2009). Recent evidence, especially from animal 
studies, suggests that BPA exposure may be 
related to insulin resistance and have a role in 
weight gain and obesity and the subsequent 
development of diabetes mellitus (Newbold 
et al. 2009; Rubin and Soto 2009). Two recent 
human studies reported that higher urinary 
BPA levels were associated with self-reported 
cardio vascular disease (CVD) (Lang et al. 
2008; Melzer et al. 2010). However, studies 
examining the relation between BPA exposure 
and more objective measures of CVD are 
needed to support this putative association.
Peripheral arterial disease (PAD) is a 
subclinical measure of atherosclerotic vascular 
disease (Newman et al. 1993) that is an 
independent predictor of subsequent incident 
CVD (Murabito et al. 2003; Newman 
et al. 1993). Criqui et al. (1992) reported 
that among persons initially free of CVD, 
an ankle–brachial index (ABI) of < 0.9 was 
associated with a hazard ratio of 6.6 for future 
risk of death from coronary heart disease 
even after adjusting for cardiovascular risk 
factors including age, sex, body mass index 
(BMI), smoking, and high cholesterol levels. 
Published guidelines (American Diabetes 
Association 2003; Hirsch et al. 2006) exist 
for defining PAD based on the ABI, which 
can be measured even in large population-
based studies (Selvin and Erlinger 2004). In 
this context, we examined the independent 
association between urinary BPA levels and 
PAD among participants in the 2003–2004 
NHANES, a representative, multi ethnic 
sample of U.S. adults.
Methods
The present study is based on data from 
NHANES 2003–2004. Detailed descriptions 
of the NHANES study design and methods 
are available elsewhere [National Center for 
Health Statistics (NCHS) 2010b]. Briefly, 
the NHANES survey included a stratified 
multi stage probability sample representa-
tive of the civilian noninstitutionalized U.S. 
population. Selection was based on counties, 
blocks, households, and individuals within 
households and included the over sampling of 
non-Hispanic blacks and Mexican Americans 
in order to provide stable estimates of 
these groups. Participants provided written 
informed consent before their participation, 
and approval was obtained from the Human 
Subjects Committee in the U.S. Department 
of Health and Human Services. Measurements 
of ABI, a subclinical measure of athero sclerosis 
(Criqui et al. 1992; Newman et al. 1993), 
were obtained for the subsample of subjects 
≥ 40 years of age.
The present study sample consisted 
of participants > 40 years of age among 
whom urinary BPA was available (n = 971). 
We further excluded participants with an 
ABI ≥ 1.5 (n = 3), which is usually related 
to non compressible blood vessels in the legs 
(Newman et al. 1993), as well as those with 
missing data on covariates included in the 
multi variable model including level of educa-
tion, smoking status, serum or fasting glu-
cose levels, systolic or diastolic blood pressure 
(SBP and DBP, respectively), and cholesterol 
levels (n = 215). This resulted in 753 partici-
pants (47.9% women), 63 of whom had 
PAD. Subjects who were excluded because 
of missing covariates were in general similar 
to the general NHANES cohort in terms of 
age, sex, race/ethnicity, and education (data 
not shown).
Exposure measurements.  Age, sex, 
race/ethnicity, smoking status, alcohol intake 
(grams per day), level of education, history 
of diabetes and oral hypoglycemic intake or 
insulin administration were assessed using a 
questionnaire (NCHS 2010b). Participants 
who had not smoked > 100 cigarettes in their 
lifetimes were considered never smokers; 
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those who had smoked > 100 cigarettes in 
their lifetimes were considered former smok-
ers if they answered negatively to the question 
“Do you smoke now?” and current smokers if 
they answered affirmatively.
Rigorous procedures with quality control 
checks were used in blood collection, and 
details about these procedures are provided 
in the NHANES laboratory/medical tech-
nologists procedures manual (NCHS 2010d). 
We used the modified hexokinase method to 
measure serum glucose levels at the University 
of Missouri Diabetes Diagnostic Laboratory 
(Columbia, MO, USA). Diabetes mellitus was 
defined, based on the recent guidelines of the 
American Diabetes Association (2011), as a 
serum glucose level of > 126 mg/dL after fast-
ing ≥ 8 hr or of > 200 mg/dL for those who 
fasted < 8 hr before their NHANES visit, a 
glycosylated hemoglobin value of > 6.5%, or a 
self-reported current use of oral hypo glycemic 
medication or insulin. Seated SBP and DBP 
were measured using a mercury sphygmoma-
nometer according to the American Heart 
Association and Seventh Joint National 
Committee recommendations (Chobanian 
2003), and up to three measurements were 
averaged. Patients were considered hyper-
tensive if they reported current use of blood 
pressure–reducing medication or had SBPs 
of > 140 mmHg or DBPs of > 90 mmHg 
(NCHS 2010b).
In NHANES 2003–2004, serum creati-
nine measurements were conducted at the 
Collaborative Laboratory Services (Ottumwa, 
IA, USA) using the Beckman Coulter 
Synchron LX20 chemistry analyzer (Beckman 
Coulter, Fullerton, CA, USA) using the 
Jaffe rate method (kinetic alkaline picrate). 
Coefficients of variation ranged from 1.5% to 
4.3% (NCHS 2010c). In a calibration sub-
study, serum creati nine assays were performed 
on 190 stored specimens from NHANES 
2003–2004 at the Cleveland Clinic labora-
tory (Cleveland, OH, USA) using the Roche 
coupled enzymatic assay that was traceable to 
gold-standard refer ence methods, including an 
isotope dilution mass spectrometric method 
for serum creati nine using standard references 
methods [NIST standard reference material 
(SRM) 967; National Institute of Standards 
and Technology, Gaithersburg, MD, USA] 
and confirmed by analysis of CAP LN-24 
(College of American Pathologists Creatinine 
Accuracy Calibration Verification/Linearity 
Survey) linearity set based on NIST-assigned 
values (Selvin et al. 2007). There were no sig-
nificant differences in results between these 
two measurements, and therefore it was con-
cluded that there was no correction neces-
sary for serum creati nine values in NHANES 
2003–2004 (Selvin et al. 2007). The glom-
erular filtration rate was estimated (eGFR) 
from serum creati nine using the  four-variable 
Modification of Diet in Renal Disease study 
equation (Levey et al. 2006) as follows: 
eGFR = 
175 × (serum creati nine in mg/dL)–1.154  
× (age in years)–0.203 × (0.742 if female)  
× (1.21 if black). 
Chronic kidney disease was defined as an eGFR 
of < 60 mL/min/1.73 m2, consistent with 
defini tions of the National Kidney Foundation 
Kidney Disease Outcome Quality Initiative 
(KDOQI; National Kidney Foundation 
2002) working group and the Kidney Disease 
Improving Global Outcomes (KDIGO) (Levey 
et al. 2006).
Previous measures of BPA in biologi-
cal matrixes involved techniques such as gas 
chromatography or high performance liquid 
chromatography (Ye et al. 2005). To achieve 
enhanced sensitivity and selectivity over pre-
vious methods, in the current NHANES, 
measures of environmental phenols were 
derivatized to alkyl or acyl derivatives before 
gas chromatography–mass spectrometry analy-
sis (NCHS 2010a). The lower limit of detec-
tion for BPA concentrations was 0.36 ng/mL.
Main outcome of interest: PAD. For study 
subjects with at least one arm and weigh-
ing ≤ 400 lb, supine SBP was measured 
with blood pressure cuffs on the right arm, 
compressing the brachial artery and the two 
posterior tibial arteries (NCHS 2010a). For 
subjects 40–59 years of age, two measure-
ments were taken at each site and averaged, 
and for patients ≥ 60 years of age, one measure 
was taken at each site. For subjects with condi-
tions precluding the measurement of the right 
arm, left brachial artery SBP was taken. Left 
and right ABI values were calculated as the 
ratio of left and right ankle SBP, respectively, 
to arm SBP. The smallest of the left and right 
ABI measurements was used. Patients with 
ABIs ≥ 1.5 (n = 3) are expected to have severe 
arterial rigidity and were excluded from the 
present analyses (Newman et al. 1993). For 
these analyses, PAD was defined as ABI < 0.9 
(American Diabetes Association 2011; Selvin 
and Erlinger 2004). Because of the selection 
criteria for ABI measurements in NHANES 
(subjects ≥ 40 years of age), subjects who had 
ABI measurements taken were significantly 
older than the general NHANES cohort but 
were otherwise similar with respect to demo-
graphic factors (data not shown).
Statistical analysis. Urinary BPA was 
categorized into tertiles (< 1.4 ng/mL, 
1.4–3.5 ng/mL, > 3.5 ng/mL). We hypothe-
sized that high BPA levels are associated with 
PAD. Odds ratios (ORs) and 95% confidence 
intervals (CIs) for PAD in association with 
BPA were calculated by taking the lowest 
tertile (tertile 1) as the referent, using multi-
variable logistic regression models. We used 
two models: one adjusted only for age and sex, 
and a multi variable model that also adjusted 
for race/ ethnicity (non-Hispanic whites, non-
Hispanic blacks, Mexican Americans, others), 
education (< high school, high school, > high 
school), household income (< $25,000, 
$25,000–54,999, ≥ $55,000), smoking status 
(never, former, current), pack-years of smok-
ing, alcohol intake (non drinker, moderate 
drinker, heavy drinker), BMI (normal, over-
weight, obese), hypertension (present, absent), 
diabetes (present, absent), urinary creati nine 
(milligrams per deciliter), eGFR (milliliters 
per minute per 1.73 m2), and total cholesterol 
(milligrams per deciliter). Trends in the OR of 
PAD across increasing urinary BPA categories 
were determined by modeling BPA as an ordi-
nal variable. We examined effect modification 
by performing stratified analysis by categories 
of sex, race/ethnicity, BMI, diabetes mellitus, 
and hypertension. We also conducted formal 
statistical tests for inter action by including 
multiplicative cross-product interaction terms 
in the multi variable logistic regression models; 
p < 0.1 was interpreted as a statistically signifi-
cant interaction. Sample weights that account 
for the unequal probabilities of selection, over-
sampling, and non-response were applied for all 
analyses using SAS (version 9.2; SAS Institute 
Inc., Cary, NC, USA) and SUDAAN soft-
ware (version 10; RTI International, Research 
Triangle Park, NC, USA); SEs were estimated 
using the Taylor series linearization method.
Results
The median (interquartile range) of uri-
nary BPA levels was 2.30 (3.60) ng/mL; the 
25th, 50th, and 75th percentile values were 
1.00, 2.30, and 4.60 ng/mL, respectively. 
Participants with higher levels of BPA were 
more likely to be men, non-Hispanic blacks, 
and former or current smokers and had higher 
levels of urinary creati nine. Table 1 shows 
these characteristics for the study popula-
tion by teriles of urinary BPA levels. Overall, 
we observed a positive association between 
increasing BPA levels and PAD on the basis 
of the age- and sex-adjusted model and the 
multi variable-adjusted model, with significant 
(p < 0.05) trend tests (Table 2). This positive 
association persisted when BPA was analyzed 
as a continuous variable (1-SD increase in log-
transformed BPA).
In a supplementary analysis, we examined 
the association between BPA levels and PAD 
after excluding n = 10 subjects with very high 
BPA values (levels > 30 ng/mL). The results 
were found to be essentially simi lar. The multi-
variable OR of PAD associated with 1 SD of 
log-transformed BPA was 1.60 (1.16–2.21). 
We also examined the association between 
increasing tertiles of BPA and self-reported 
CVD, and the magnitude of association 
was found to be weaker than that for PAD. 
Bisphenol A and peripheral arterial disease
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Compared to tertile 1 of BPA (referent), 
the multi variable-adjusted OR (95% CI) of 
self-reported CVD was 1.09 (0.18–6.60) for 
tertile 2, and 1.83 (1.01–3.31) for tertile 3 
(p-trend = 0.02).
Discussion
In a large multiethnic, nationally representa-
tive sample, we found that increasing serum 
BPA levels were strongly associated with 
PAD. The observed association was indepen-
dent of the confounding factors of smoking, 
BMI, alcohol intake, diabetes mellitus, hyper-
tension, and serum cholesterol level. Our 
study adds to the emerging evidence suggest-
ing a role for environmental exposure to BPA 
in cardiovascular disease in humans (Lang 
et al. 2008; Melzer et al. 2010). Furthermore, 
because PAD and low ABI are markers of 
athero sclerosis, our findings suggest that 
potential effects of BPA on athero sclerosis 
may be a mechanism underlying the previ-
ously reported association between BPA expo-
sure and self-reported CVD (Lang et al. 2008; 
Melzer et al. 2010).
BPA is an environmental chemical used 
as a constituent monomer in polycarbonate 
plastics, which are used extensively in drink 
containers and food packaging and in the 
production of oxidants used in the lining 
of canned goods (Vandenberg et al. 2009). 
Exposure to BPA is believed to be mainly 
through dietary intake with additional expo-
sure through water, dental sealants, inhalation 
of household dusts, and exposure through 
skin (Vandenberg et al. 2009). Recent studies 
from NHANES data have documented that 
> 93–95% of the general U.S. population has 
measurable concentrations of BPA metabo-
lites in their urine (Calafat et al. 2005, 2008).
Several lines of recent evidence suggest 
that an association between urinary BPA lev-
els and PAD may be biologically plausible. 
Animal studies have suggested that BPA 
exposure may have a role in CVD develop-
ment through several mechanisms, including 
the role of BPA in weight gain and obesity 
development potentially through its action 
on pre adipocytes (Masuno et al. 2005; 
Phrakonkham et al. 2008), role as an estro-
gen (Rubin and Soto 2009), potential inter-
actions with estrogen-related receptor gamma 
(Matsushima et al. 2008), actions as a thyroid 
hormone antagonist (Moriyama et al. 2002), 
role as a peroxisome proliferator–activated 
receptor gamma antagonist (Wright et al. 
2000) and its role in influencing pancreatic 
endocrine function (Ropero et al. 2008). 
Alonso-Magdalena et al. (2006) showed that 
mice with long-term exposure to environ-
mentally relevant levels of BPA developed 
hyperinsulinemia, insulin resistance, and 
glucose intolerance. Furthermore, in ani-
mal models BPA has been shown to induce 
endothelial cell injury mediated through oxi-
dative stress (Hennig et al. 2002; Ooe et al. 
2005; Stegeman et al. 1995) and elevations in 
lipids (Marmugi et al. 2012). However, there 
are few studies in humans for comparison.
Two of the few human studies (Lang et al. 
2008; Melzer et al. 2010) reported positive 
associations between urinary BPA levels and 
self-reported CVD. Also, BPA levels were 
found to be associated with abnormal liver 
function enzymes and higher levels of fasting 
glucose, insulin, and HOMA-IR (homeo stasis 
model of assessment—insulin resistance) (Lang 
et al. 2008; Melzer et al. 2010), all points sug-
gesting that BPA may have a role in CVD. It 
is in this context that our results on objectively 
measured ABI to define PAD are important. 
In the present study, we have demonstrated 
a significant, positive association between 
higher BPA  levels and PAD that persisted after 
adjustment for multiple confounders.
The main strengths of our study include 
its nationally representative sample and use 
of rigorous study methods to collect the 
data and the availability of extensive data on 
confounders (NCHS 2010a, 2010b). The 
main study limitation is that the present 
study is cross- sectional in nature, therefore 
making it impossible to confirm that exposure 
preceded the outcome. Another limitation is 
the possibility of residual confounding. For 
example, despite adjusting for education and 








Unweighted sample size 253 240 252
Age (years) 56.7 ± 0.6 55.6 ± 0.7 55.5 ± 0.9
Female (%) 56.5 54.8 42.7
Race/ethnicity (%)
Non-Hispanic whites 76.3 81.4 75.0
Non-Hispanic blacks 3.7 9.1 14.4
Mexican Americans and others 20.0 9.5 10.6
Education (%)
< High school 16.5 19.7 16.8
High school 24.0 29.5 27.6
> High school 59.5 50.8 55.6
Income (%)
< $25,000 20.1 23.3 21.2
$25,000–$54,999 29.9 40.1 40.0
≥ $55,000 50.0 36.6 38.8
Smoking status (%)
Never 51.7 52.2 39.2
Former 30.8 30.1 37.5
Current 17.5 17.7 23.3
Pack-years of smoking 12.6 ± 1.6 13.5 ± 1.0 17.4 ± 2.2
Alcohol intake (%)
Nondrinker 29.9 41.1 39.5
Moderate drinker 55.1 42.5 40.0
Heavy drinker 15.0 16.4 20.5
BMI (%)
Normal weight (< 25 kg/m2) 31.5 32.5 23.3
Overweight (25–30 kg/m2) 38.7 35.0 38.6
Obese (BMI ≥ 30 kg/m2) 29.8 32.5 38.1
Diabetes (%) 11.0 14.4 16.1
Hypertension (%) 43.4 45.9 51.5
Urinary creatinine (mg/dL) 70.2 ± 5.2 120.5 ± 4.3 161.8 ± 5.2
eGFR (mL/min/1.73 m2) 81.5 ± 1.3 80.5 ± 1.3 80.1 ± 1.9
Total cholesterol (mg/dL) 210.9 ± 2.3 209.6 ± 3.5 207.0 ± 3.3
Urinary BPA (ng/mL) 0.7 ± 0.02 2.4 ± 0.05 10.0 ± 1.1
PAD (%) 2.8 4.1 9.1
Data presented are mean ± SE except where indicated.
Table 2. Association between urinary BPA and PAD.
BPA (ng/mL)






Tertile 1 (< 1.4) 253 (2.8%) 1 (referent) 1 (referent)
Tertile 2 (1.4–3.6) 240 (4.1%) 1.53 (0.39, 6.04) 1.10 (0.22, 5.39)
Tertile 3 (> 3.6) 252 (9.1%) 3.73 (2.03, 6.86) 2.69 (1.02, 7.09)
p-Trend < 0.0001 0.01
1-SD increase in log-transformed 
BPA (ng/mL)b
1.57 (1.30, 1.90) 1.38 (1.11, 1.72)
aAdjusted for age, sex, race/ethnicity, education, income, smoking status, pack-years of smoking, alcohol intake, BMI, 
hypertension, diabetes, urinary creatinine, eGFR, and total cholesterol. b1 SD of log-transformed BPA = 1.15 ng/mL.
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income, the observed association between BPA 
levels and PAD may be at least partly explained 
by residual confounding by low socioeconomic 
status. Future prospective studies are required 
to confirm or disprove our findings. A third 
limitation is that because ABI measures were 
available only in NHANES 2003–2004, 
we are not able to examine data from the 
recent NHANES cycles such as NHANES 
2005–2006, where BPA levels may be lower. 
Fourth, the use of urinary BPA levels measured 
from a single spot sample is likely to result 
in some misclassifi cation because of the large 
variability of BPA. Therefore, to provide the 
best approach for BPA exposure assessment, 
expert panels have recommended collection 
of multiple (rather than single) spot urine 
samples and study designs that consider 
important exposure contributors such as the 
time of the day of sampling (e.g., in relation 
to food consumption) and the time of last 
urination (World Health Organization/Food 
and Agriculture Organization of the United 
Nations Expert Panel 2011). Finally, urinary 
BPA levels may not be reflective of the free, 
unconjugated, circulating BPA in blood, which 
is considered to be the biologically active form. 
Future studies examining the health effects 
of BPA should preferably measure this free, 
unconjugated part of BPA in serum.
Conclusions
In a nationally representative sample of U.S. 
adults, higher BPA levels were positively 
associated with PAD after adjusting for con-
founding factors such as age, sex, smoking, 
BMI, alcohol intake, diabetes, hypertension, 
and cholesterol levels. Although our findings 
must be confirmed in other studies, they pro-
vide preliminary evidence that environmental 
exposure to BPA may contribute to PAD.
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